Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

GHRSVery BullishCorporate Developmentsnews

High materiality10/10

FDA Lifts Hold On GH Research's Depression Drug Trial After Two Years

Jan 5, 2026, 9:56 AM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The FDA lifting the clinical hold marks significant progress for GHRS. Similar past FDA approvals often led to substantial stock price increases for biopharma companies.

AI summary

What happened, with direct paths to the underlying reporting

FDA lifted the clinical hold on GH001, a key milestone for GHRS. GH001 shows significant improvement in treatment-resistant depression patients. Global pivotal program for GH001 expected to launch in 2026. GHRS shares gained 34.52% after FDA announcement. Competitors are advancing their treatments in a growing market.

FDA lifted the clinical hold on GH001, a key milestone for GHRS.
GH001 shows significant improvement in treatment-resistant depression patients.
Global pivotal program for GH001 expected to launch in 2026.
GHRS shares gained 34.52% after FDA announcement.
Competitors are advancing their treatments in a growing market.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

FDA Lifts Hold On GH Research's Depression Drug Trial After Two Years

GH Research rises on TRD data, FDA hold lift, and Phase 3 progress

GH Research Misses Q1 Earnings Estimations but Progresses in Trials

Depression-Focused GH Research Shares Could See Significant Upside: Analyst